Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
Status:
Terminated
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This is a single center, prospective, open-label, randomized trial at the University of
Minnesota Medical Center,Fairview.
Primary objectives are to determine if rejection episodes and loss rates, graft survival,
level of renal graft function, and patient survival rates with a Campath/MMF-based (Group 1)
immunosuppressive protocol are lower than, or equal to, our protocol using thymoglobulin,
tacrolimus, and MMF (Group 2).
This study will investigate the first protocol that is both steroid-free and calcineurin
inhibitor-free in pancreas after kidney transplant recipients.
Phase:
Phase 4
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute